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Immunoblotting of human liver sonicates, after SDS-polyacrylamide gel electrophoresis, demonstrated the 
presence of a 40 kDa protein, corresponding to the subunit of alanineglyoxylate aminotransferase, in six 
controls and three patients with primary hyperoxaluria type 1 (peroxisomal alanineglyoxylate aminotrans- 
ferase deficiency). This immunoreactive 40 kDa protein was absent in a further nine patients. Subcellular 
fractionation of patients’ livers showed that the 40 kDa protein, when present, was located mainly in the 
peroxisomes. In a heteroxygote liver, the 40 kDa protein was also mainly peroxisomal and paralleled the 
distribution of alanine:glyoxylate aminotransferase activity. 
Hyperoxaluria; Peroxisomal disorder; SDS-PAGE; Immunoblotting; Alanineglyoxylate aminotransferase; 
Liver pathology; (Human) 
1. INTRODUCTION 
Primary hyperoxaluria type 1 (PHl) is an 
autosomal recessive inborn error of glyoxylate 
metabolism which leads to increased synthesis and 
excretion of oxalate and glycolate [ 11. The cause of 
the disease has been shown to be a deficiency of the 
hepatic peroxisomal enzyme alanine :glyoxylate 
aminotransferase (EC 2.6.1.44) [2]. There is con- 
siderable clinical heterogeneity within PH 1, which 
is to some extent paralleled by enzymic 
heterogeneity [3]. AGT from human liver has been 
shown to be a homodimer with subunits of about 
40 kDa [4]. 
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In this study we have examined livers from con- 
trols, PHI patients (homozygotes), a PHl 
heterozygote, and patients with other forms of 
primary hyperoxaluria for the presence of proteins 
immunologically cross-reactive with AGT. In addi- 
tion we have investigated the subcellular localiza- 
tion of this immunoreactive material in a CRM + 
PH 1 homozygote and heterozygote. 
2. EXPERIMENTAL 
2.1. Livers 
For the subcellular fractionation experiments, 
the liver samples were obtained fresh, either by 
open biopsy or by complete removal of the organ 
prior to hepatic transplantation. The homogeniza- 
tion and fractionation on isopycnic sucrose gra- 
dients was performed as described [5]. For the 
other experiments, liver samples, frozen at 
-2O”C, were thawed and sonicated for 30 s in 
10 vols of ice-cold 100 mM potassium phosphate 
buffer, pH 7.4, containing 1OOpM pyridoxal 
phosphate. Any non-suspended fibrous material 
was removed by low-speed centrifugation. 
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2.2. Assays Table 1 
AGT activity and GGT activity were assayed by 
a modification of the method of Rowsell et al. [6]. 
Protein was measured by the method of Lowry et 
al. [7]. 
Relationship between AGT activity and immunoreactive 
40 kDa protein in control and hyperoxaluric livers 
2.3. Immunoblotting 
AGT was purified to a single silver-staining 
band on SDS-PAGE by a modification of the 
method of Thompson and Richardson [8] and was 
used to raise antisera in rabbits (New Zealand 
White) by conventional methods” 
Samples of liver sonicates (containing 50 pg pro- 
tein) or sucrose gradient fractions (10 ~1 containing 
up to 1OOpg protein) were electrophoresed on 
SDS-PAGE, as described by Laemmli [9], prior to 
electroeluting onto nitrocellulose membranes by 
the procedure of Towbin et al. [lo]. The 
nitrocellulose membranes were then incubated 
with AGT antiserum (diluted 1 in 500 in phosphate 
buffered saline (PBS), pH 7.2, containing 3% milk 
proteins) for 4 h at room temperature. After 
washing with PBS, the bound antibodies were 
visualized using horseradish peroxidase conjugated 
to goat anti-rabbit IgG and developed using 
4-chloro-1-naphthol as substrate [ 111. 
Livers AGT N CRM 
Controls (3.76-8.38) 5 + 
PHI Homozygotes 
(group 1) (0.00-0.37) 9 - 
(group 2) 0.08 1 + 
0.17 1 + 
0.58 1 + 
PHI Heterozygote 1.45 1 + 
Others 
(A) 4.57 1 + 
(B) 4.18 1 + 
(C) 2.29 1 + 
AGT units = pmol/h per mg protein, corrected for 66% 
cross-over from GGT [12]; N = number of individuals; 
CRM = presence or absence of immunologically cross- 
reacting material of 40 kDa on SDS-PAGE. Patients 
with other forms of primary hyperoxaluria were (A) 
primary hyperoxaluria type 2 (hyperoxaluria + 
hyperglyceric aciduria), (B) putative oxalate hyper- 
absorption (hyperoxaluria only), (C) mild type 1 variant 
(mild hyperoxaluria + extreme hyperglycolic aciduria) 
3. RESULTS 
Liver sonicates from 5 controls, 12 pyridoxine- 
resistant PHI patients, 3 patients with other forms 
of primary hyperoxaluria, and an individual who 
was heterozygous for PHI were subjected to SDS- 
PAGE and immunoblotting, along with purified 
AGT. The latter gave a single immunoreactive 
band of about 40 kDa, agreeing with the previous- 
ly established subunit molecular mass [4]. All the 
liver sonicates gave a band of about 55 kDa, but 
the presence or absence of a cross-reacting band of 
40 kDa, corresponding to AGT protein, depended 
on the source of the liver. As expected, all of the 
controls, the PHl heterozygote and the three pa- 
tients with non-type 1 forms of primary hyperox- 
aluria produced a cross-reacting band at 40 kDa. 
However, of the patients with PHI, only 3 
demonstrated a band at 40 kDa, whereas 9 did not 
(table 1). 
Two PHI homozygote livers (one CRM + and 
one CRM - , with respect to the 40 kDa protein) 
and one PHl heterozygote liver (CRM +) were 
subcellularly fractionated by isopycnic sucrose gra- 
dient centrifugation, and the distribution of 
40 kDa cross-reacting material, when present, was 
compared with the distribution. :of” AGT activity 
(fig. lA,B and C). In the heteroz?gote the distribu- 
tion of the immunoreactive 4&kDa protein was 
similar to that of AGT activity, and peaked in the 
peroxisomal fractions (fig.lA). Although AGT ac- 
tivity was present at the top of the gradient, little 
or no 40 kDa protein was found there. This activi- 
ty is probably due to a different enzyme, GGT [2]. 
In the CRM + homozygote PH 1 liver, the distribu- 
tion of the immunoreactive 40 kDa protein was 
similar to that in the heterozygote, i.e. mainly 
peroxisomal, despite there being no detectable 
peroxisomal AGT activity (fig.lB). The CRM - 
PHl homozygote liver had no detectable 40 kDa 
protein in any of the subcellular fractions and 
neither did it possess any peroxisomal AGT activi- 
ty (fig.lC). 
At this stage the identity of the 55 kDa protein 
is unknown. Not only was it present in all the 
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Fig. 1. Subcellular distribution of immunoreactive 
protein and AGT activity on sucrose gradients. Samples 
were run on SDS-PAGE and immunoblotted as 
described in section 2. Enzyme activity (not corrected for 
GGT cross-over) is expressed as ymol/h per ml of 
gradient fraction, corrected for 1 mg of protein loaded. 
‘p’, ‘m’ and ‘c’ mark the position of the peroxisomal, 
mitochondrial and cytosolic markers, respectively. (A) 
PHl heterozygote; (B) CRM+ PHl homozygote; (C) 
CRM- PHl homozygote. The liver sonicate AGT 
activities (corrected for GGT cross-over [12]) in these 
individuals were (A) 1.45, (B) 0.08, (C) 0.04. Normal 
range = 3.76-8.38. 
livers, but also it appeared to be spread across the 
top two-thirds of the gradient, which was very dif- 
ferent to that of the 40 kDa AGT subunit protein. 
4. DISCUSSION 
These data demonstrate that PHl is 
heterogeneous, not ., only clinically [l] and en- 
zymologically [3], but also immunologically. Im- 
munoblotting was unable to detect an 
immunoreactive 40 kDa protein in 9 out of 12 PHl 
livers which possessed O-8% of the mean control 
AGT activity, suggesting that the protein either is 
not synthesised or is degraded very rapidly. 
However in the remaining 3 PHI livers im- 
munoreactive AGT protein of normal molecular 
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mass could be detected. Only one of these CRM + 
PHI livers possessed significant AGT activity 
(12% of the mean control value), the other two 
having insignificant activities (l-4%). In the 
CRM+ PHl liver, that was subcellularly frac- 
tionated, the distribution of immunoreactive AGT 
protein, was normal (i.e. mainly peroxisomal), 
zdespite there being a complete deficiency of perox- 
isomal AGT activity. 
NOTE ADDED IN PROOF 
Preabsorption of the antiserum with liver 
homogenate from the CRM- PHl homozygote 
removed the immunoreactive signal to the 55 kDa 
protein in the liver from the CRM+ PHI homo- 
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zygote, without reducing the reaction to the 
40 kDa protein (AGT). This indicates that the 
55 kDa protein is immunologically unrelated to 
AGT. 
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